Record July ADV in interest rate, equity index, energy, agricultural and metals productsInternational ADV grew 32% to 8.8 million contracts

CHICAGO, Aug. 4, 2026 /PRNewswire/ — CME Group, the world’s leading derivatives marketplace, today reported its highest July average daily volume (ADV) on record at 27 million contracts, an increase of 23% year-over-year. Market statistics are available in greater detail at https://cmegroupinc.gcs-web.com/monthly-volume.

July 2026 ADV across asset classes includes:

Interest Rate ADV of 12.6 million contractsEquity Index ADV of 8.2 million contractsEnergy ADV of 2.6 million contractsAgricultural ADV of 2 million contractsForeign Exchange ADV of 811,000 contractsMetals ADV of 788,000 contractsCryptocurrency ADV of 237,000 contracts ($10.3 billion notional)

Additional July 2026 product highlights compared to July 2025:

Interest Rate ADV increased 17%SOFR futures ADV increased 9% to 3.6 million contractsU.S Treasury futures and options ADV increased 22% to 7 million contracts10-Year U.S. Treasury Note futures ADV increased 13% to 1.8 million contracts5-Year U.S. Treasury Note futures ADV increased 13% to 1.3 million contracts10-Year U.S. Treasury Note options ADV increased 46% to 1.2 million contracts2-Year U.S. Treasury Note futures ADV increased 32% to 873,000 contracts30-Day Fed Funds futures ADV increased 60% to 660,000 contractsEquity Index ADV increased 48%Micro E-Mini Nasdaq-100 futures ADV increased 159% to 3 million contractsE-Mini S&P 500 futures ADV increased 24% to 1.4 million contractsMicro E-Mini S&P 500 futures ADV increased 27% to 1.1 million contractsE-Mini S&P 500 options ADV increased 8% to 1.1 million contractsEnergy ADV increased 9%WTI Crude Oil futures ADV increased 17% to 953,000 contractsHenry Hub Natural Gas futures ADV increased 2% to 454,000 contractsMicro WTI Crude Oil futures ADV increased 175% to 179,000 contractsAgricultural ADV increased 15%Corn futures ADV increased 16% to 441,000 contractsSoybean futures ADV increased 12% to 293,000 contractsChicago SRW Wheat futures ADV increased 53% to 176,000 contractsForeign Exchange ADV increased 9%Japanese Yen futures ADV increased 39% to 184,000 contractsMetals ADVMicro Gold futures ADV increased 41% to 287,000 contractsMicro Silver futures ADV increased 123% to 49,000 contracts1-Ounce Gold futures ADV increased 417% to 51,000 contractsInternational ADV increased 32% to 8.8 million contracts, with EMEA ADV up 29% to 6.3 million contracts and APAC ADV up 41% to 2.1 million contractsMicro Products ADVMicro E-mini Equity Index futures and options ADV of 4.4 million contracts represented 54% of overall Equity Index ADV, Micro Energy futures accounted for  7.1% of overall Energy ADV and Micro Metals futures accounted for 53% of overall Metals ADVBrokerTec overall average daily notional value (ADNV) increased 15% to $1.056 trillionU.S. Repo ADNV increased 9% to $393 billionEuropean Repo ADNV increased 20% to €356 billionU.S. Treasury ADNV increased 13% to $91 billion EBS Spot FX ADNV increased 25% to $70 billion and FX Link ADV increased 38% to 55,000 contracts ($5.2 billion notional per leg)Customer average collateral balances to meet performance bond requirements for rolling 3-months ending June 2026 were $150 billion for cash collateral and $170.4 billion for non-cash collateral

As the world’s leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, cryptocurrencies, energy, agricultural products and metals.  The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform.  In addition, it operates one of the world’s leading central counterparty clearing providers, CME Clearing. 

CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc.  CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc.  NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc.  COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group LTD. The S&P 500 Index is a product of S&P Dow Jones Indices LLC (“S&P DJI”). “S&P®”, “S&P 500®”, “SPY®”, “SPX®”, US 500 and The 500 are trademarks of Standard & Poor’s Financial Services LLC; Dow Jones®, DJIA® and Dow Jones Industrial Average are service and/or trademarks of Dow Jones Trademark Holdings LLC. These trademarks have been licensed for use by Chicago Mercantile Exchange Inc. Futures contracts based on the S&P 500 Index are not sponsored, endorsed, marketed, or promoted by S&P DJI, and S&P DJI makes no representation regarding the advisability of investing in such products. All other trademarks are the property of their respective owners. 

CME-G

View original content:https://www.prnewswire.com/news-releases/cme-group-july-volume-hits-new-record-of-27-million-contracts-up-23-year-over-year-302842336.html

SOURCE CME Group

Acquisition expands Company’s integrated device care platform to 45 corporately owned locations across six provinces

EDMONTON, AB , Aug. 4, 2026 /CNW/ — Dr. Phone Fix Canada Corporation (TSXV: DPF) (“Dr. Phone Fix” or the “Company”), one of Canada’s fastest-growing and award-winning integrated device care platforms, is pleased to announce that it has completed its previously announced acquisition of the assets of Martin Cell Phone Solutions Ltd. (“Martin”) an established device repair business located in Saint John, New Brunswick (the “Transaction”).

The acquisition establishes Dr. Phone Fix’s presence in New Brunswick and expands the Company’s corporately owned retail network to 45 locations across six (6) provinces, further advancing its strategy of building a scalable national integrated device care platform through disciplined acquisitions, selective greenfield expansion and strategic partnerships.

The Transaction adds an established revenue-generating retail location, a loyal customer base and an immediate operating presence in New Brunswick, strengthening the Company’s growing footprint in Atlantic Canada following its recent expansion into Nova Scotia.

“Our objective is to build a scalable national integrated device care platform by acquiring quality businesses and integrating them into our centralized operating model,” said Piyush Sawhney, Founder and Chief Executive Officer of Dr. Phone Fix. “This transaction reflects the disciplined acquisition strategy we intend to replicate as we continue expanding our national integrated device care platform, which we believe can create meaningful shareholder value. This strategy includes a disciplined purchase price, modest upfront cash, vendor alignment and operational upside through integration.”

Transaction Details

Under the terms of the asset purchase agreement governing the Transaction, Dr. Phone Fix has acquired the assets of Martin for total consideration of $144,440.48, which includes $9,440.48 of inventory.

The purchase price is structured to preserve cash and align vendor incentives with post-closing performance, and includes:

$50,000 in cash paid at closing;$50,000 of deferred and performance-based payments tied to revenue thresholds; andthe issuance of common shares of the Company as partial consideration, aligned with long-term value creation.

In connection with the Transaction, the Company issued 352,849 common shares of the Company to Martin, representing an aggregate value of $44,440.48 (the “Consideration Shares”). The Consideration Shares are subject to a statutory hold period of four months and one day in accordance with applicable securities laws. The Transaction has received approval from the TSX Venture Exchange.

Continued Growth

The Canadian device repair and pre-owned device sale industry remains highly fragmented, presenting opportunities for disciplined consolidation by well-capitalized operators with scalable operating platforms. Management believes this presents opportunities for disciplined consolidation through acquisitions of established businesses that can benefit from Dr. Phone Fix’s centralized operating platform.

Prior to closing, Martin generated approximately $350,000 in annual revenue based on historical financial information provided by the vendor. Dr. Phone Fix expects to enhance the performance of the acquired location by integrating it into the Company’s centralized operating platform, including procurement, inventory management, pricing optimization, marketing, training and standardized store-level operating processes. Management believes these capabilities provide opportunities to improve operational efficiency and support long-term store performance.

Mr. Sawhney continued, “We continue to see attractive acquisition opportunities across Canada within a fragmented industry. Our strategy is not simply to increase store count, but to build a stronger national platform with increasing operating scale, greater purchasing leverage and enhanced capabilities to serve customers, carriers, insurers and OEM partners across Canada.”

The Company intends to maintain uninterrupted service for Matin’s existing customers while gradually integrating the location into the Dr. Phone Fix platform.

Dr. Phone Fix continues to evaluate additional acquisition opportunities across Canada that complement its existing geographic footprint and support its long-term growth strategy.

About Dr. Phone Fix

Dr. Phone Fix is an award-winning Canadian integrated device care platform providing repair, refurbishment, certified pre-owned devices, trade-in solutions and related services through its growing national retail network. Founded in 2019, the Company now operates 45 corporately owned retail locations nationwide, delivering fast, reliable, and environmentally conscious repair services alongside a curated selection of certified pre-owned devices and premium accessories. Dr. Phone Fix maintains relationships with OEMs, insurance partners and certified suppliers, ensuring consistently high-quality standards across its national footprint. With a mission rooted in sustainability, transparency, and exceptional customer service, Dr. Phone Fix is focused on advancing the device care and resale ecosystem in Canada.

www.docphonefix.com.

NEITHER THE TSXV NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information can be identified by words such as: “intend”, “believe”, “estimate”, “expect”, “may”, “will” and similar references to future periods. Forward looking information includes, but is not limited to, the expected benefits and synergies from the Transaction, including anticipated revenue enhancements and operational improvements; the Company’s intention to expand its national footprint; expectations regarding the performance of acquired locations; and expectations regarding future growth and profitability. Although the Company believes that, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that the Company may not realize the anticipated benefits of the Transaction; and the risk that the future plans of the Company may differ from those that currently are contemplated. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

SOURCE Dr. Phone Fix

New programs, expected to begin revenue contribution Q4 2026, extend Dario’s integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company’s provider-backed care strategy

AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario’s participation in reimbursement-driven healthcare services

NEW YORK, Aug. 4, 2026 /PRNewswire/ — DarioHealth Corp. (NASDAQ: DRIO) (the “Company”, “DarioHealth” or “Dario”), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed cardiometabolic platform with the launch of Dario Women™ and Dario Sleep™. The two new programs address important drivers of cardiometabolic health through an integrated care experience combining AI-powered engagement, behavioral support and access to licensed healthcare providers.

The new offerings come as demand from large enterprise payers for multi-condition solutions continues to rise, and single point offerings are phased out. While increasing the indications supported by its platform, Dario has further expanded into provider-backed care to broaden participation in reimbursement-driven healthcare services.

Both Dario Women™ and Dario Sleep™ are expected to roll out to the Company’s Fortune 500 and other clients in Fall 2026. Recurring revenue contribution per engaged member per month for the digital health platform is expected to commence in the fourth quarter of 2026, with revenue from the provider-backed care services anticipated at the end of 2026 and into the beginning of 2027. The new programs are expected to expand revenue opportunities across Dario’s existing enterprise customer base by allowing employers and health plans to address additional high-cost clinical needs through the same integrated platform.

“Dario continues to execute on our strategy of integrating provider-backed care throughout our expanding chronic condition platform,” said Erez Raphael, Chief Executive Officer of Dario. “Women’s health and sleep represent significant opportunities to improve cardiometabolic outcomes while expanding the value we deliver to employers, health plans and members. As we continue adding clinical capabilities to our platform, we strengthen our ability to support members throughout their healthcare journey while creating new opportunities to grow revenue through healthcare services that extend beyond digital engagement.” 

Dario Women: Supporting Women’s Cardiometabolic Health

Dario Women, developed in-house and native to Dario’s solution, supports members navigating perimenopause and menopause, life stages frequently associated with weight changes, sleep disruption, metabolic changes and increased cardiometabolic risk, with one in three women developing metabolic syndrome during menopause transition1.

The program combines AI-powered engagement, personalized human-led behavioral coaching and access to licensed healthcare providers in one, connected member experience. Eligible members may receive clinical evaluation for hormone replacement therapy (HRT), when medically appropriate, following a comprehensive clinical assessment conducted in accordance with evidence-based clinical guidelines and applicable regulations.

Dario Sleep: Connecting Sleep Health to Cardiometabolic Care

Dario Sleep addresses obstructive sleep apnea (OSA), a significant contributor to cardiometabolic disease and rising healthcare costs.

Published research has shown that untreated OSA patients incur approximately 2.5× higher annual healthcare costs than individuals without OSA.2 Cardiometabolic patients with OSA also generate approximately 50% higher annual medical costs, representing an average increase of more than $6,185 per member per year.3

The Dario Sleep program enables eligible members to complete a one-night, clinical-grade home sleep test with real-time data transmitted directly to licensed healthcare providers for evaluation. Based on individual clinical needs, providers determine appropriate treatment pathways, which may include positional therapy, oral appliance therapy, CPAP therapy or GLP-1 treatment when clinically appropriate.

“Our goal is to connect members with the right care through one coordinated experience,” said Lara Dodo, Chief Operating Officer of Dario. “By integrating AI-powered engagement, behavioral coaching and provider-backed clinical care within one platform, we help members access appropriate treatment while giving employers and health plans a more comprehensive solution for managing interconnected chronic conditions.”

Members enrolled in Dario Women and Dario Sleep continue their care journey through Dario’s integrated healthcare platform, which combines connected devices, AI-powered insights, personalized coaching and provider-backed clinical care across diabetes, hypertension, weight management, ergonomic posture, behavioral health, women’s health and sleep.

1 Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women’s Health Across the Nation. Arch Intern Med. 2008;168(14):1568-1575. doi:10.1001/archinte.168.14.1568. PMID: 18663170. https://pubmed.ncbi.nlm.nih.gov/18663170/

2 Zappala P, et al. The Global Socioeconomic Burden of Obstructive Sleep Apnea: A Comprehensive Review. Healthcare (Basel). 2025;13(17):2115. https://doi.org/10.3390/healthcare13172115

3 Patel U. Sleep apnea drives average medical costs up 50% for patients with cardio/obesity. Evernorth Research Institute, January 26, 2024. https://www.evernorth.com/articles/sleep-apnea-cardiodiabesity-medical-costs 

About DarioHealth Corp. (Nasdaq: DRIO)

DarioHealth (Nasdaq: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company’s integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.

Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario’s AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected launch and implementation of the programs; the timing of anticipated revenue contribution by the programs; that the new programs are expected to expand revenue opportunities across Dario’s existing enterprise customer base; and the benefits and uses of the Company’s platform and programs. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310

Rob Halpern
SVP Marketing
irteam@dariohealth.com 

Logo – https://mma.prnewswire.com/media/2866807/6030938/Dario_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/dario-expands-provider-backed-cardiometabolic-platform-with-new-womens-health-and-sleep-solutions-aligning-with-client-demand-302841434.html

SOURCE DarioHealth Corp.